What is the core purpose of Novartis's $3.2 billion deal with Alteogen, and how does the Hybrozyme platform work?

The core purpose of Novartis's up to $3.2 billion deal with Alteogen is not to develop new drugs, but to license the Hybrozyme platform—a technology designed to convert intravenous biologic infusions into subcutaneous injections. This delivery method improvement aims to enhance patient convenience and help defend existing biologics against biosimilar competition. The platform works by using an enzyme to temporarily dissolve tissue that obstructs the absorption of large molecules, thereby enabling faster uptake of the drug; this mechanism has already been validated clinically by Merck's Keytruda.

Why is Novartis investing so heavily in a drug delivery platform rather than a new therapeutic?

Novartis is investing up to $3.2 billion in Alteogen's Hybrozyme platform because the strategic priority is improving the delivery method of existing biologic drugs—not creating new ones—specifically to strengthen their competitive position against biosimilars. By converting intravenous infusions into subcutaneous injections, the platform enhances patient accessibility and convenience while leveraging a proven biological mechanism: an enzyme that temporarily breaks down tissue barriers to allow faster absorption of large-molecule therapeutics, a principle already validated in practice with Merck's Keytruda.

This $3.2 Billion Novartis Bet Is Not a New Drug. It Is a Better Way to Take One

Sep 3, 2026

Novartis committed $3.2 billion to license Alteogen's Hybrozyme platform, enabling subcutaneous delivery of existing biologics to combat biosimilar competition. The enzyme technology improves absorption and is validated by Merck's Keytruda.

24/7 Wall St.

2026-09-03

This $3.2 Billion Novartis Bet Is Not a New Drug. It Is a Better Way to Take One

This $3.2 Billion Novartis Bet Is Not a New Drug. It Is a Better Way to Take One

FAQ